**Efficacy Outcomes in Clinical Trials of Atopic Dermatitis Treatments: A Systematic Literature Review**


Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Dermavant Sciences, Inc., Montclair, NJ, USA; Putnam, Newcastle upon Tyne, Tyne and Wear, UK

**INTRODUCTION**

- Complete skin clearance is a key atopic dermatitis (AD) treatment goal.
- Treatment efficacy in AD trials is evaluated using a range of clinical measures, with the Investigator Global Assessment (IGA) as a key endpoint.
- Multiple forms of the IGA scale have been utilized across trials; these include the Investigator Static Global Assessment (ISGA) and the Validated Investigator Global Assessment for AD (vIGA-ADTM).

**OBJECTIVE**

- To compare differences in published efficacy outcomes in recent clinical trials of FDA-approved AD treatments for adults and children.

**MATERIALS AND METHODS**

- A systematic literature search was conducted using MEDLINE, Embase, Cochrane Library databases, and hand searches.
- The search identified randomized, single-, and open-label trials in patients with mild, moderate, and severe AD published between January 1, 2016 and August 16, 2023 (full manuscript publications) or August 16, 2022 and August 16, 2023 (congress abstracts).
- Trials included patients with varying severity of AD.
- Trials treated agents were agents that had been recently FDA approved for AD.
- Efficacy endpoints included endpoints: IGA=0 or 1 and ≥2-grade improvement from baseline or achieving IGA=0.
- IGA scale scores usually range from 0 (clear) through to 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe), but may contain differences in the definitions, level of detail, or response".

**RESULTS**

- Table 1. Number of Publications for Baseline AD Severity by Type of AD Treatment and Key Efficacy Endpoints Reported
- Table 2. Number of Publications for Baseline AD Severity by Type of AD Treatment and Key Efficacy Endpoints Reported

**CONCLUSIONS**

- This systematic literature search of AD trial publications from 2018 on therapies recently approved by the FDA revealed several gaps in available efficacy outcomes data.
- No trials assessed a topical therapy for moderate to severe AD, and complete disease clearance was not reported for any topical treatments.

**REFERENCES**


**ACKNOWLEDGMENTS**

- This study was funded by Dermavant Sciences, Inc. R.C. has served as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, ASLAN, Beigene, Boehringer Ingelheim, F. Hoffmann-La Roche, Inc., Gilead Sciences, Inc., Genentech, Inc., Kyowa Kirin, Inc., LEO Pharma, LLC, Medivation, Inc., Merck & Co., Inc.,Novartis, Pfizer, Inc., Regeneron, Sanofi, and UCB Pharma. A.B.S., J.F., M.V., A.M.T., and D.F. are employees of Dermavant Sciences, Inc. with stock options.

- The IGA category includes trials that evaluated this endpoint using the IGA, ISGA, or vIGA-ADTM scales.